We examined the effect of PF-06463922 on ALK activity and cell proliferation in neuroblastoma cell lines, in comparison to the well-characterized clinical ALK TKI crizotinib (Christensen et al., 2007). This evidence concerns the gene ALK and neuroblastoma.